Charles River Laboratories International, Inc. logo
Charles River Laboratories International, Inc. (CRL)
Compare

CRL Income Statement

Revenue, expenses, and profitability analysis

CRL Quarterly Income Statement (USD)

Quarterly ReportTTM
03/28/2026
12/27/2025
09/27/2025
06/28/2025
03/29/2025
12/31/2024
09/28/2024
06/29/2024
1.283B279.319M307.855M338.792M357.067M317.732M284.244M349.021M353.713M
4.027B995.830M994.227M1.005B1.032B984.168M1.003B1.010B1.026B
Cost of Goods Sold
2.744B716.511M686.372M666.060M675.068M666.436M718.305M660.742M672.404M
28.0%28.0%31.0%33.7%34.6%32.3%28.4%34.6%34.5%
Total Operating Expenses
808.983M159.422M187.635M204.993M256.933M243.063M451.931M231.616M202.061M
0.000.000.000.000.000.000.000.000.00
716.195M159.422M187.635M177.589M191.549M177.799M195.708M199.213M169.791M
474.050M119.897M120.220M133.799M100.134M74.669M-167.687M117.405M151.652M
12.0%12.0%12.1%13.3%9.7%7.6%-16.7%11.6%14.8%
-165.423M-29.942M-294.099M87.200M71.418M35.978M-216.791M91.241M119.653M
Interest Income
4.569M1.033M1.017M1.422M1.097M1.404M1.835M1.528M3.010M
105.887M26.742M23.775M25.403M29.967M27.884M28.234M30.284M32.769M
Other Income/Expense
-639.473M-149.839M-414.319M-46.599M-28.716M-38.691M-49.104M-26.164M-31.999M
-184.650M-14.843M-276.555M54.422M52.326M25.469M-215.699M68.679M89.988M
17.420M-15.140M-17.809M31.644M18.725M10.100M-3.044M20.946M25.392M
-1.5%-1.5%-27.8%5.4%5.1%2.6%-21.5%6.8%8.8%
804.204M187.048M198.497M197.767M220.892M184.226M-86.453M209.723M238.504M
EBITDA Margin
18.8%18.8%20.0%19.7%21.4%18.7%-8.6%20.8%23.2%
350.099M67.151M78.277M85.164M119.507M120.364M102.104M88.198M86.082M
EPS Basic
-3.75-0.30-5.621.111.060.50-4.221.341.75
-3.76-0.30-5.621.101.060.50-4.221.331.74
Shares Outstanding
48.951M48.951M49.216M49.213M49.149M50.677M51.138M51.394M51.551M
Diluted Shares Outstanding
48.951M48.951M49.216M49.426M49.316M50.853M51.138M51.583M51.846M

CRL Annual Income Statement (USD)

Annual Report
12/27/2025
12/28/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
1.226B1.332B1.503B1.463B1.335B1.074B958.311M840.067M
4.015B4.050B4.129B3.976B3.540B2.924B2.621B2.266B
Cost of Goods Sold
2.790B2.718B2.627B2.513B2.206B1.850B1.663B1.426B
30.5%32.9%36.4%36.8%37.7%36.7%36.6%37.1%
Total Operating Expenses
717.734M1.104B885.295M811.676M744.776M640.812M607.160M508.684M
0.000.000.000.000.000.000.000.00
743.073M751.003M747.855M665.098M619.919M528.935M517.622M443.854M
507.839M227.347M617.261M650.975M589.862M432.729M351.151M331.383M
12.6%5.6%14.9%16.4%16.7%14.8%13.4%14.6%
-99.503M93.114M581.284M622.987M480.710M447.114M304.084M281.681M
Interest Income
4.940M8.575M5.196M780K652K834K1.522M812K
107.029M126.288M136.710M59.291M73.910M86.433M60.882M63.772M
Other Income/Expense
-607.342M-134.233M-35.977M-27.988M-109.152M14.385M-47.067M-49.702M
-144.338M10.297M474.624M486.226M390.982M364.304M252.019M226.373M
42.660M67.823M100.914M130.379M81.873M81.808M50.023M54.463M
-3.6%0.3%11.5%12.2%11.0%12.5%9.6%10.0%
911.151M581.143M1.032B986.148M820.160M768.471M563.061M507.232M
EBITDA Margin
22.7%14.3%25.0%24.8%23.2%26.3%21.5%22.4%
403.312M361.741M314.124M303.870M265.540M234.924M198.095M161.779M
EPS Basic
-2.910.209.279.577.777.355.174.72
-2.910.209.229.487.607.205.074.62
Shares Outstanding
49.564M51.380M51.227M50.812M50.293M49.550M48.730M47.947M
Diluted Shares Outstanding
49.564M51.628M51.451M51.301M51.425M50.611M49.693M49.018M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Wilmington, MA
18,700 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
James C. Foster